Posted in | News | Nanobusiness

Nanotechnology Corporation to Establish Russian-Israeli Investment Fund

RUSNANO, established in 2007 by the Federal law No.139-FZ to enable Government policy in the field of Nanotechnology, announces a tender for selecting the partner (managing company) to establish the Russian-Israeli investment fund. This fund should become one of the elements of the foreign technology transfer system and will allow to increase the number of Israeli technology-based investment projects which assume localization of production operations in Russian Federation.

The Fund’s target size is US$100 million, up to 50% of which shall be committed by RUSNANO. The rest financing shall be raised by the managing company selected during the tender. The total fund size may be extended up to US$200 million. The additional commitment will also be split 50/50 between RUSNANO and other investors.

According to the tender conditions, managing company to establish the Russian-Israeli investment fund should have appropriate professional knowledge and experience, propose confirmed information about total asset value under management of the management company and/or its partner (partner is a company, which owns not less than 25% of the management company) and confirmed value of the aggregated commitments of the co-investors to contribute in the Fund. Management company should also present projects for the Fund’s pipeline which meet the following criteria:

Israeli technology;
Investment size - 3 to 8 mln USD;
IRR not less than 30%.

The Russian Corporation of Nanotechnologies (RUSNANO) was established in 2007 by the Federal law No.139-FZ to enable Government policy in the field of Nanotechnology.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.